{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-020389","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.985668+00:00","generated_at":"2026-06-05T03:15:48.421613+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell amends supply agreement: Re-Tain deal terminates Nov 30, 2024 if FDA not approved","bullets":["Agreement auto-terminates on Nov 30, 2024 unless FDA approval for Re-Tain is received by then.","New payment terms: 75% invoiced monthly during production; 25% final balance on dispatch after FDA OK.","If no FDA approval by Nov 30, 2024, final balance is invoiced and agreement expires.","Updated Schedule 7 projects ~160,000 commercial units with expiration 4Q25-1Q26."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-020389","json":"https://secwatch.observer/filing/0001213900-24-020389.json","markdown":"https://secwatch.observer/filing/0001213900-24-020389.md","text":"https://secwatch.observer/filing/0001213900-24-020389.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024020389/0001213900-24-020389-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024020389/ea0201306-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T03:15:48.421613+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"524d2568e2142e18c14f3eeb50ae0d5e1bcb119e","claim":"IMMUCELL CORP /DE/ amended Amending Agreement with Norbrook Laboratories Limited (effective 2024-03-04).","evidence_excerpt":"On March 4, 2024, ImmuCell Corporation (the “Company”) entered into an Amending Agreement (the “Amendment”) with Norbrook Laboratories Limited (“Norbrook”), which Amendment amends that certain Development Services and Commercial Supply Agreement, dated September 5, 2019, by and between the Company and Norbrook (as amended to date, the “Agreement”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/811641/000121390024020389/0001213900-24-020389-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"supply"},{"label":"Counterparty","value":"Norbrook Laboratories Limited"},{"label":"Effective","value":"2024-03-04"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}